undamentalytics Newsletter
Sign in

Immunitybio, Inc. balance sheet

At the end of fiscal 2025, Immunitybio, Inc. had total assets of $502m, total liabilities of $1.00bn and shareholders' equity of −$500m. It held $88.3m in cash against $326m of debt: net debt of $238m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents0591768241776351811052651438876
Receivables—0————————024353
Inventory——————————0812
Total current assets—592982051328956112334141294185315439
Goodwill———————————11—
Total assets—61367317250182143221469362504383502629
Accounts payable—124632121121————
Deferred revenue (current)—1————————————
Total current liabilities—26132127126836950158556277
Short-term debt———————————12—
Long-term debt—————————2415770——
Total debt000000000673577286326415
Total liabilities—211243236223407138121,0908711,0011,674
Shareholders' equity−458356293219146121−120−242−447−587−489−500−1,047
Net debt (negative = net cash)−0−59−176−8−24−17−76−35−181569311142238339
Shares outstanding——81m82m79m79m394m382m398m422m—853m1,012m1,053m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IBRX vs NUVBBEAM vs IBRXABUS vs IBRXIBRX vs KPTI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immunitybio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immunitybio, Inc.